You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Single-session bronchial thermoplasty for severe asthmatics guided by HXe MRI

    SBC: XEMED LLC            Topic: NHLBI

    DESCRIPTION provided by applicant Roughly one million Americans with inadequately controlled severe persistent asthma have a particularly high risk of exacerbations hospitalizations and death and account for a per patient health care burden exceeding $ annually Bronchial thermoplasty BT applies radiofrequency heating to airway smooth muscle reducing its thickness and hyper reactivity This novel mi ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Magnetic Flow Sorter for Pancreatic Islet Isolation

    SBC: TECHSHOT, INC.            Topic: 200

    DESCRIPTION provided by applicant Techshot Inc has successfully completed SBIR Phase I and Phase II research demonstrating that magnetically labeled porcine islets of Langerhans can be isolated from contaminating exocrine tissue by flow sorting using a quadrupole magnetic separator andquot Quadrasepandquot designed for that purpose Magnetically sorted islets are superior in morphology and ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Novel anti-viral agents to treat influenza

    SBC: ALEXANDER BIODISCOVERIES, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Yearly influenza epidemics affect about of the worldandapos s population and estimates of annual mortality range from including approximately deaths and hospitalizations in the United States In addition the likelihood of a severe pandemic caused by a newly emergent strain of influenza virus is very high given that three such pandemics were recorded in the th centu ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Safe and effective anti CD154 antibodies for therapeutic intervention

    SBC: Immunext, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant In both animal proof of concept studies and preliminary clinical trials there is ample data demonstrating the potential therapeutic benefits o CD blockade for treatment of GVHD organ transplantation and autoimmune diseases However development of CD as a therapeutic has been impeded by antibody toxicity observed in early clinical trials GVHD is a ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Distributed REMD Simulation for Probing Alzheimer Molecular Mechanisms

    SBC: PARABON COMPUTATION, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE:

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Safe And Effective Anti-CD154 Antibodies For Therapeutic Intervention

    SBC: Immunext, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): There is compelling evidence that ?CD154 treatment has great potential in autoimmunity and graft rejection. Autoimmunity. Clinical efficacy of ?CD154 treatment has been seen in Lupus and idiopathic thrombocytopenia. In addition, Principal Investigator Dr. Noelle's clinical experience with ?CD154 is based on a Phase I trial in remitting/ relapsi ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of

    SBC: AARDEN PHARMACEUTICALS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Inhibitors of Mycobacterial Protein Tyrosine Phosphatase B (mPTPB) for therapy of tuberculosis Aarden Pharmaceuticals Project Summary/Abstract The need exists for a new, breakthrough therapeutic for tuberculosis (TB). Current treatment regimens with toxic chemotherapeutic drugs are too long, causing poor compliance which results in reduced efficacy and the emer ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Elucidation of Antisickling Molecules in a Botanical with Antisickling Activity

    SBC: INVENUX, LLC            Topic: NCCAM

    DESCRIPTION: New therapeutic agents are urgently needed for the treatment of sickle cell disease (SCD), the world's most common genetic disease. Our long-term goal is to develop a drug for use in children that prevents the inexorable progression of SCD. SCD affects approximately 100,000 people in the United States and millions worldwide. It kills more children in Africa than HIV, but while HI ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government